Sanofi to Acquire Translate Bio for $3.2B
Upgrades drug formulation capabilities and accelerates development of licensed programs in vaccines and potential to explore other therapeutic areas.
August 5, 2021
by contractpharma
Sanofi to acquire mRNA therapies developer Translate Bio for $3.2bn
Sanofi has signed a definitive agreement to acquire 100% outstanding shares of a messenger RNA (mRNA) therapies company, Translate Bio, for a total equity value of nearly $3.2bn, or $38 per share in cash.
August 4, 2021
by pharmaceutical-technology
Sanofi plans €400m investment in mRNA vaccines ‘centre of excellence’
French pharma company Sanofi has announced that it will invest €400m into a new facility focused on solely on the development and delivery of next-generation mRNA-based vaccines.
June 30, 2021
by pharmatimes
Phase I trial of mRNA-based influenza vaccine begins
The trial will assess a monovalent mRNA-based vaccine candidate against seasonal influenza caused by the A/H3N2 strain.
June 24, 2021
by europeanpharmaceuticalreview
Sanofi and Translate Bio start clinical trial for mRNA flu vaccine
The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.
June 23, 2021
by expresspharma
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2 ...
March 19, 2021
by worldpharmanews
mRNA COVID-19 vaccine from Sanofi will not ready this year: CEO
A COVID-19 vaccine candidate developed by Sanofi and US group Translate Bio “will not be ready this year,” said the company’s CEO to Le Journal du Dimanche newspaper.
February 18, 2021
by expresspharma